[Clinical trials with mercapto polycytidylic acid in the treatment of acute childhood leukemia (author's transl)].
Mercapto Polycytidylic acid (MPC) is a potent inhibitor of oncornaviral reverse transcriptase. The fact that this enzyme has been found in human leukemic cells, has let to the clinical trials of MPC in the treatment of childhood acute leukemia. This report discribes the first pilot clinical trial on 23 patients. The results are encouraging, and have let to a second pilot study including other clinical centers on the clinical efficacy of MPC in the treatment of leukemia.
D000208:Acute Disease; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008297:Male; D011066:Poly C / Q000008:administration & dosage / Q000627:therapeutic use*; D011131:Polyribonucleotides / Q000627:therapeutic use*
D011131:Polyribonucleotides; D011066:Poly C
Behandlungsversuche mit Mercaptopolycytidylsäure bei akuten Leukämien des Kindes.